Should butalbital-containing analgesics be banned? Yes.
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In the United States analgesic-overuse headache is often caused by butalbital-containing analgesics. These agents can cause physical and psychological dependency, and dangerous withdrawal syndromes. Butalbital-containing analgesics have already been banned in several European countries. They are proven effective in tension-type headache, but not in migraine; there are many alternative treatments for migraine and tension-type headache. In the 20 years since analgesic overuse headache was widely recognized, butalbital overuse has remained distressingly common. It is time to ban these agents.
References and Recommended Reading
Newman LC, Lipton RB, Stewart WF: Severe daily headache in a population sample: results from the American migraine study (submitted for publication). 1998 (UnPub).
Diamond S, Dalessio DJ: Drug abuse in headache. In The Practicing Physician’s Approach to Headache. Edited by Diamond S, Dalessio DJ. Baltimore: Williams & Wilkins; 1982:114–121
Wilkinson M: Introduction. In Drug Induced Headache. Edited by Diener HC, Wilkinson MS. Berlin: Springer-Verlag; 1988:1–2.
Mathew NT: Drug induced headache. Neurol Clin 1990, 8:903–912.PubMed
Saper JR: Chronic headache syndromes. Neurol Clin 1989, 7:387–412.PubMed
Silberstein SD, Lipton RB, Solomon S, Mathew NT: Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache 1994, 34:1–7.CrossRef
Andersson PG: Ergotism: the clinical picture. In Drug Induced Headache. Edited by Diener HC, Wilkinson MS. Berlin: Springer-Verlag; 1988:16–19
Rapoport AM, Weeks RE, Sheftell FD, et al.: The “analgesic washout period”: a critical variable evaluation in the evaluation of headache treatment efficacy. Neurology 1986, 36:100–101.
Warner JS: Rebound headaches: a review. Headache 1999, 10:207–219.
Kudrow L: Paradoxical effects of frequent analgesic use. Adv Neurol 1982, 33:335–341.PubMed
Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalalgia 1988, 8:1–96.CrossRef
Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996, 47:871–875.PubMed
Scholz E, Diener HC, Geiselhart S, Wilkinson M: Drug-induced headache: does a critical dosage exist? In Drug-Induced Headache. Edited by Diener HC. Berlin: Springer-Verlag; 1988:29–43.
Bowdler I, Killian J, Gänsslen-Blumberg S: The association between analgesic abuse and headache: coincidental or causal. Headache 1990, 30:494.
Lance F, Parkes C, Wilkinson M: Does analgesic abuse cause headache de novo? Headache 1988: 61–62.
Friedman AP: Assessment of Fiorinal with codeine in the treatment of tension headache. Clin Ther 1986, 8:703–721.PubMed
Friedman AP, Boyles WF, Elkind AH, et al.: Fiorinal with codeine in the treatment of tension headache: the contribution of components to the combination drug. Clin Ther 1988, 10:303–315.PubMed
Friedman AP, Diserio FJ: Symptomatic treatment of chronically recurring tension headache: a placebocontrolled, multicenter investigation of Fioricet and acetaminophen with codeine. Clin Ther 1987, 10:69–81.PubMed
Glassman JM, Soyka JP: Muscle contraction (tension) headache: a double blind study comparing the efficacy and safety of meprobamate-aspirin with butalbital-aspirinphenacetin-caffeine. Curr Ther Res 1980, 28:904–909.
Goldstein J, Gawel MJ, Winner P, et al.: Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine. Headache 1988, 38:516–522.CrossRef
Hwang DS, Mietlowski MJ, Friedman AP: Fiorinal with codeine in the management of tension headache: impact of placebo response. Clin Ther 1987, 9:201–222.PubMed
Thorpe P: Controlled and uncontrolled studies on “Fiorinal-PA” for symptomatic relief in tension headache. Med J Aust 1970, 2:180–181.PubMed
von Graffenried B, Hill RC, Nuesch E: Headache as a model for assessing mild analgesic drugs. J Clin Pharmacol 1980, 20:131–144.
vonGraffenried B, Nuesch E: Nonmigrainous headache for the evaluation of oral analgesics. J Clin Pharmacol 1980, 10:225–231.
Sellers EM, Hoornweg K, Busto UE, Romach MK: Risk of drug dependence and abuse posed by barbiturate-containing analgesics. Can J Clin Pharmacol 1999, 6:18–25. A review of the safety of barbiturates alone and in combination with analgesics.PubMed
McLean W, Boucher EA, Brennan M, et al.: Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Can J Clin Pharmacol 2000, 7:191–197. A summary on the effectiveness, safety, and risks associated with barbiturate-containing analgesics and on the approach to management of withdrawal for barbiturate-containing analgesics.PubMed
Hobbs WR, Rall TW, Verdoorn TA: Hypnotics and sedatives: ethanol. In The Pharmacological Basis of Therapeutics. Edited by Goodman LS, Gilman A. New York: McGraw-Hill; 1996:361–396.
Micromedex®: Butalbital. Martindale: The Complete Drug Reference. (Volume 107). 2000. Micromedex® Healthcare Series.
Kay DC, Blackburn AB, Buckingham JA, Karacan I: Human pharmacology of sleep. In Pharmacology of Sleep. Edited by Williams RL, Karacan L. New York: John Wiley & Sons; 1976:83–210.
Mendelson WB, Gillin JC, Wyatt RJ: Human Sleep and Its Disorders. New York: Plenum Press; 1977.
Ciraulo DA, Greenblatt DJ: Sedative-, hypnotic-, or anxiolyticrelated disorders. In Comprehensive Textbook of Psychiatry. Edited by Kaplan HI, Sadock BJ. Baltimore: Williams & Wilkins; 1995:872–887.
Sullivan JT, Sellers EM: Treatment of the barbiturate abstinence syndrome. Med J Aust 1986, 145:456–458.PubMed
Fraser HF, Wikier A, Essig CF, Isbell H: Degree of physical dependence induced by secobarbital or pentobarbital. JAMA 1958, 166:126–129.
Lipton RB, Stewart WF, VonKorff M: Burden of migraine: societal costs and therapeutic opportunities. Neurology 1997, 48:4–9.
Lipton RB, Stewart WF, VonKorff M: The burden of migraine: a review of cost to society. Pharmaco Economics 1994, 6:215–222. Direct and indirect costs for migraine society.
Diener HC, Gerber WD, Geiselhart S: Short and long-term effects of withdrawal therapy in drug-induced headache. In Drug-Induced Headache. Edited by Diener HC, Wilkinson M. Berlin: Springer-Verlag; 1988:133–142.
Osterhaus JT, Gutterman DL, Plachetka JR: Healthcare resource and lost labor costs of migraine headache in the United States. Pharmaco Economics 1992, 2:67–76.
VonKorff M, Stewart WF, Simon DS, Lipton RB: Migraine and reduced work performance: a population-based diary study. Neurology 1998, 50:1741–1745.
- Should butalbital-containing analgesics be banned? Yes.
Current Pain and Headache Reports
Volume 6, Issue 2 , pp 151-155
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links